Performance analysis of Liminatus Pharma (LIMN)
Annual Return
Since May 1, 2025, LIMN has had an average annual return of -97.47%, underperforming the benchmark SPY, which returned +27.71% annual.
| 2026 | 2025 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| -81.35% | -93.94% |
Monthly Return
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Annually Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -9.90% | -54.03% | -31.87% | +18.71% | -19.70% | -32.52% | +2.73% | -81.35% | |||||
| 2025 | -46.08% | +105.34% | -43.77% | -56.78% | -38.39% | -16.77% | -25.14% | -41.34% | -93.94% |
Drawdown analysis of Liminatus Pharma (LIMN)
The maximum drawdown for the LIMN was -99.63%, occurring on Jun 25, 2026. This drawdown has not yet recovered.
The current LIMN drawdown is -99.57%.
Since May 1, 2025 LIMN has experienced the following drawdowns:
- 50% or more: 3 times
- 40% or more: 3 times
- 30% or more: 3 times
- 20% or more: 3 times
- 10% or more: 3 times
| Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -99.63% | Jun 24, 2025 | 252 | Jun 25, 2026 | Ongoing | Ongoing | Ongoing |
| -57.27% | Jun 9, 2025 | 2 | Jun 11, 2025 | 8 | Jun 24, 2025 | 10 |
| -54.72% | May 1, 2025 | 18 | May 28, 2025 | 5 | Jun 4, 2025 | 23 |
| -1.54% | Jun 5, 2025 | 1 | Jun 6, 2025 | 1 | Jun 9, 2025 | 2 |